Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00461396 · ClinicalTrials.gov registry record
Success of Titration, Analgesics, and B.E.T.A Nurse Support on Acceptance Rates in Early Multiple Sclerosis (MS) Treatment With Betaseron
A clinical trial, sponsored by Bayer.
- Completed
- Registry status
- 104
- Enrollment target
NCT00461396 is a clinical trial that has completed, run by Bayer. The registered enrollment target is 104 participants.
The verdict
NCT00461396 has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- 104 participants
- Enrollment target
Study Summary
* The primary aim of this study is to evaluate the impact of titration, analgesics, and 12 month telephone follow-up period from the B.E.T.A nurse program upon adherence to treatment with Betaseron in patients with a first clinical demyelinating event suggestive of Multiple Sclerosis (MS) and patients with onset of RRMS within the past 12 months * Secondary outcomes include analysis of the following parameters: progression of clinical severity by the expanded disability status scale (EDSS score), health related quality of life (HrQoL), and safety. * Exploratory outcomes include changes over time in cytokine and neurotrophic factor production by immune cells and visual function as assessed by visual examination, OCT measurements and a neuro-ophthalmologic Health-Related Quality of Life questionnaire (NEI-VFQ-25) with 10-item supplement.
Interventions
- DRUG Interferon-1beta (Betaseron, BAY86-5046)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 104 participants |
| Start Date | 2007-05 |
| Est. Completion | 2009-11 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00461396
The ClinicalTrials.gov registry entry for NCT00461396 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 104 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Interferon-1beta (Betaseron, BAY86-5046) is the first listed.
NCT00461396 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00461396 about?
NCT00461396 is a clinical study titled "Success of Titration, Analgesics, and B.E.T.A Nurse Support on Acceptance Rates in Early Multiple Sclerosis (MS) Treatment With Betaseron". * The primary aim of this study is to evaluate the impact of titration, analgesics, and 12 month telephone follow-up period from the B.E.T.A nurse program upon adherence to treatment with Betaseron in patients with a first clinical demyelinating event suggestive of Multiple Sclerosis (MS) and patien...
What is the current status of trial NCT00461396?
This trial is currently completed. The enrollment target is 104 participants. The study started on 2007-05. Estimated completion is 2009-11.
What interventions are being tested in trial NCT00461396?
The interventions under investigation include: Interferon-1beta (Betaseron, BAY86-5046) (DRUG).
Who is sponsoring clinical trial NCT00461396?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.